search button
Open Access

Use of clinicopathological factors to predict prognosis of fertility‑sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia

  • Authors:
    • Xiaobo Zhang
    • Xiaoya Zhao
    • Chen Wang
    • Shanshan Lu
    • Yiqin Wang
    • Yijiao He
    • Jianliu Wang
    • Danhua Shen

  • View Affiliations

  • Published online on: December 16, 2022     https://doi.org/10.3892/ol.2022.13638
  • Article Number: 52

  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The incidence of endometrial endometrioid carcinoma (EEC) has been gradually increasing over the past decade. Fertility‑sparing therapy with progestin is a treatment option for EEC or endometrial atypical hyperplasia (AH). The present study evaluated the role of numerous prognostic factors following fertility‑sparing therapy for EEC or AH. Furthermore, the present study assessed the strength of various clinicopathological indicators for the prediction of treatment efficacy. A retrospective analysis was performed of patients with EEC and AH who received fertility‑sparing therapy between August 2013 and September 2021 at Peking University People's Hospital (Beijing, China). Endometrial specimens were obtained from each patient after 3 months of treatment and at the end of the fertility‑sparing therapy, before treatment efficacy and prognosis were evaluated using the χ2 test. Furthermore, the protein expression levels of EEC biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), paired box 2 (PAX2), PTEN and p53 were assessed using immunohistochemistry. The overall complete response (CR) rate of fertility‑sparing treatment in the EEC group was 67.39% (31/46), whereas that in the AH group was 86.49% (32/37). The difference between the CR rates in the EEC and AH groups was statistically significant (P<0.05). There was no association between prognosis after treatment and ER, PAX2, PTEN or Ki‑67 expression in the initially untreated AH or EEC groups. However, tissues with >50% positive PR expression were demonstrated to have a higher CR rate compared with those with ≤50% positive PR expression in both the EEC and AH groups. Furthermore, the PAX2‑positive group tended to demonstrate higher CR rates compared with the PAX2‑negative group in the patients with EEC. In conclusion, these data suggested that fertility‑sparing therapy is effective for patients with EEC and AH who wish to remain fertile after treatment. Specifically, in the AH group, a higher proportion of patients achieved a CR whilst also achieving this more rapidly. Furthermore, PR was demonstrated to be a useful marker for the evaluation of EEC and AH.
View Figures
View References

Related Articles

Journal Cover

February-2023
Volume 25 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang X, Zhao X, Wang C, Lu S, Wang Y, He Y, Wang J and Shen D: Use of clinicopathological factors to predict prognosis of fertility‑sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia. Oncol Lett 25: 52, 2023
APA
Zhang, X., Zhao, X., Wang, C., Lu, S., Wang, Y., He, Y. ... Shen, D. (2023). Use of clinicopathological factors to predict prognosis of fertility‑sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia. Oncology Letters, 25, 52. https://doi.org/10.3892/ol.2022.13638
MLA
Zhang, X., Zhao, X., Wang, C., Lu, S., Wang, Y., He, Y., Wang, J., Shen, D."Use of clinicopathological factors to predict prognosis of fertility‑sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia". Oncology Letters 25.2 (2023): 52.
Chicago
Zhang, X., Zhao, X., Wang, C., Lu, S., Wang, Y., He, Y., Wang, J., Shen, D."Use of clinicopathological factors to predict prognosis of fertility‑sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia". Oncology Letters 25, no. 2 (2023): 52. https://doi.org/10.3892/ol.2022.13638